{"entity":{"id":"nct05805501","kind":"trial","name":"A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cel","aka":[],"tldr":"A phase 2 trial of Tiragolumab, Pembrolizumab, Axitinib in renal cell carcinoma, run by Hoffmann-La Roche, active and no longer recruiting.","summary":"A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma is a phase 2 interventional study registered as NCT05805501 by Hoffmann-La Roche, with 199 participants enrolled, started 2023-04-21 and due to reach its primary completion in 2026-10-08. Interventions recorded: Tobemstomig, Tiragolumab, Pembrolizumab, Axitinib. Conditions listed: Renal Cell Carcinoma. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05805501","url":"https://clinicaltrials.gov/study/NCT05805501"}],"tags":["ctgov-ingest"],"related":[],"cancers":["rcc"],"sections":[],"technologies":[],"targets":[],"drugs":["tiragolumab","pembrolizumab","axitinib"],"companies":["roche-genentech"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05805501","phase":"2","setting":"A Randomized Open Label Phase II Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma","sponsor":"Hoffmann-La Roche","enrolled":199,"outcomes":[]},"route":"/trials/nct05805501/","neighbours":{"cancer":[{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"}],"drug":[{"id":"axitinib","kind":"drug","name":"Axitinib","route":"/drugs/axitinib/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"tiragolumab","kind":"drug","name":"Tiragolumab","route":"/drugs/tiragolumab/"}],"company":[{"id":"roche-genentech","kind":"company","name":"Roche / Genentech","route":"/companies/roche-genentech/"}]}}